Digital transformation is one of the biggest drivers of change in the pharmaceutical industry today. Artificial intelligence, big data and other digital technologies are transforming everything from the research and development of new drugs to the relationships between patients, physicians, and payers.
However, many industry leaders still need to increase their knowledge on these topics, to avoid hindering strategic decisions and the successful adoption of digital innovations.
What distinguishes this program is its explicitly international perspective. By combining insights from global reference markets with a deep understanding of the Brazilian context, participants gain a multidimensional view that goes far beyond a national perspective. While a purely domestic approach often focuses on local regulatory or structural challenges, the international lens reveals transferable success factors, implementation models, and measurable outcomes from mature digital health ecosystems. This contrast enables participants to identify what can realistically be adapted to Brazil’s healthcare environment and what requires systemic change—thereby turning international experience into actionable national strategy.
The Brazilian digital health landscape presents regulatory peculiarities (ANVISA, LGPD, telemedicine) and structural challenges (dispersed data, interoperability, cultural barriers), which need to be understood for innovation to be viable and sustainable.
This training program was designed specifically for directors and managers in the national and multinational pharmaceutical industry, focusing on:
Participants will have a solid foundation for understanding, planning, and leading digital health and artificial intelligence initiatives, positioning their companies competitively in a market increasingly driven by data and innovation.
Prof Dr Jefferson Fernandes – www.specismed.com
Dr Andreas Keck – www.syte-institute.com
Directors and managers (national/multinational) in the areas: R&D, regulatory affairs, pharmacovigilance, medical, access/market, marketing/commercial, operations/supply, IT/data, legal & compliance, emerging areas (innovation, biotechnology).
This in-company program offers several predefined modules with diverse content that can be targeted at different company audiences. The content of the modules can be tailored to the company’s needs. The duration of each module will vary depending on the desired program density, with a minimum of three hours per module.
Online, synchronous lectures with live interaction with the participants. For better interaction and learning during the course, we suggest that each group of participants has no more than 20 people.
20
Selected faculty with extensive field experience will bring a pragmatic and real-world view to the course.
The program was designed considering the target audience and the main areas of the pharmaceutical company impacted by artificial intelligence and digital health.
Participants will gain strategic insight, actionable tools, and a practical roadmap to:
Training Program for Pharmaceutical Companies in Brazil
